Conversations and Cases: Integrating Recent Progress in the Treatment and Management of Relapsed Refractory Multiple Myeloma (Segment 2)

Tuesday, March 28, 2023, 8:00 AM - Thursday, February 29, 2024, 11:59 PM

AMA PRA Category 1 Credits™ (0.25 hours), AMA PRA Category 1 Credits™ Designated (0.25 hours)

Segment 2: Early Relapse with Comorbidities

Despite advances in the initial treatment strategies of multiple myeloma, many patients will experience an early relapse. The further management of such patients can be challenging given the various options and complex patient- and disease-related factors.

Conversations and Cases in Multiple Myeloma is a roundtable discussion activity designed to inform and guide on integrating recent progress in the management of early relapse. The expert faculty will discuss different cases with early relapse and provide guidance on safely using approved and emerging therapy to improve outcomes. The activity will be supported by downloadable slides that have key discussion and teaching points.

There are no fees for participating in and receiving CME credit for this online activity.

Click 'register now' to access this activity.

1. Review latest guidelines and recommendations for the treatment and management of early relapse in multiple myeloma (MM)
2. Appraise the rationale and mechanism of action and for novel agents that have been recently approved and are under development for early relapse in MM
3. Evaluate key clinical evidence on newly approved and emerging therapies including those targeting BCMA for early relapse in MM
4. Recognize clinical trial endpoints, and patient- and disease-related factors to safely guide treatment decisions in early relapse in MM
5. Optimize therapy of diverse patients with early relapsed MM to address disparities, improve outcomes, and minimize adverse effects

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Cincinnati and Practice Point Communications. The University of Cincinnati is accredited by the ACCME to provide continuing medical education for physicians.

The University of Cincinnati designates this enduring material activity for a maximum of .25 AMA PRA Category 1 Credit™. Physicians should claim only the credits commensurate with the extent of their participation in the activity.

Physician Assistants (AAPA), Nurse Practitioners (AANP), and Nurses (ANCC) can count ACCME activities certified for AMA PRA Category 1 Credit™ for professional credit reporting purposes. All healthcare professionals, other than physicians, should inquire with their respective certifying or licensing boards to confirm.

Disclosure of Ineligible Relationships (COI) Policy
In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education and the University of Cincinnati policy, all faculty, planning committee members, and other individuals, who are in a position to control content, are required to disclose all relationships with ineligible companies* (commercial interests) within the last 24 months. All educational materials are reviewed for fair balance, scientific objectivity, and levels of evidence. The ACCME requires us to disqualify from involvement in the planning and implementation of accredited continuing education any individuals (1) who refuse to provide this information or (2) whose conflicts of interests cannot be mitigated.

All relevant relationships have been mitigated. The following disclosures were made:

Planning Committee Disclosures

Practice Point Communications
Nirupama Mulherkar
Martin Stevens
Jill Valone

University of Cincinnati
Robert Ellis, MD, Physician Review
Susan Tyler, PhD, Associate Dean, CCPD/CME Office
Heather Muskopf, Program Manager, CCPD/CME Office

The University of Cincinnati and Practice Point Communications and the peer/content reviewers for this activity have no relationships to disclose.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Neither the University of Cincinnati nor Practice Point Communications, recommends the use of any agent outside of the labeled indications.

Disclosure of Ineligible Relationships (COI) Policy

In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education and the University of Cincinnati policy, all faculty, planning committee members, and other individuals, who are in a position to control content, are required to disclose all relationships with ineligible companies* (commercial interests) within the last 24 months. All educational materials are reviewed for fair balance, scientific objectivity, and levels of evidence. The ACCME requires us to disqualify from involvement in the planning and implementation of accredited continuing education any individuals (1) who refuse to provide this information or (2) whose conflicts of interests cannot be mitigated.

*Companies that are ineligible to be accredited in the ACCME System (ineligible companies) are those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant relationships have been mitigated. The following disclosures were made:

FACULTY DISCLOSURES

Jesus Berdeja, MD
Director, Multiple Myeloma Research
Sarah Cannon Research Institute

Research Funding: 2Seventy Bio, Abbvie, Acetylon, Amgen, Bluebird Bio, Bristol Myers Squibb, C4 Therapeutics, CaRsgen, Cartesian Therapeutics, Celgene, Celularity, CRISPR Therapeutics, EMD Sorono, Fate Therapeutics, Genentech, GSK, Ichnos Sciences, Incyte, Janssen, Karyopharm, Lilly, Novartis, Poseida, Sanofi, Takeda, Teva, Zentalis
Consultant: Bluebird Bio, Bristol Myers Squibb, Celgene, CRISPR Therapeutics, Janssen, Kite Pharma, Legend Biotech, Secure Bio, Takeda

Paul Richardson, MD
Director, Clinical Research at Jerome Lipper Multiple Myeloma Center
Dana Farber Cancer Institute

Research Funding: Bristol Myers Squibb, Celgene, Karyopharm, Oncopeptides, Takeda
Consultant: AstraZeneca, Bristol Myers Squibb, Celgene, GSK, Janssen, Karyopharm, Oncopeptides, Sanofi, Secura Bio, Takeda

Saad Usmani, MD
Chief, Myeloma Service
Memorial Sloan Kettering Cancer Center

Researcher: Abbvie, Amgen, Bristol Myers Squibb, Celgene, Gilead, GSK, Janssen, Merck, Sanofi, Seattle Genetics, Skyline DX, Teneobio
Advisory Board: Abbvie, Amgen, Bristol Myers Squibb, Celgene, Genentech, Gilead, GSK, Janssen, Merck, Oncopeptides, Sanofi, Seattle Genetics, Securabio, Skyline DX, Tenebio
Speaker: Amgen, Bristol Myers Squibb, Celgene, Janssen, Sanofi

Mitigation of Relevant Financial Relationships

The University of Cincinnati adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control content of a CME activity, including faculty, planners, reviewers, or others, are required to disclose all financial relationships with ineligible entities (commercial interests) over the last 24-months. All relevant relationships have been mitigated prior to the commencement of the activity.

Information regarding the new updated ACCME Standards for Integrity and Independence in Accredited Continuing Education can be found on the ACCME website.

This educational activity is supported by an educational grant from Bristol Myers Squibb and Janssen Pharmaceuticals.